BackHarvard Bioscience Overview

Harvard Bioscience Total Liabilities

Harvard Bioscience's total liabilities is $68M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$67.89M
4.50% YoYΔ $2.93M vs prior year quarter

Peer average

Loading

Harvard Bioscience Total Liabilities History

Loading

Harvard Bioscience vs. peers: Total Liabilities Comparison

Loading

Harvard Bioscience Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Harvard Bioscience (HBIO) FAQ

As of the most recent data (March 2026), HBIO shows a total liabilities of $68M. That compares with $65M in the prior-year period — up 4.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HBIO's total liabilities is now $68M (was $65M) — a 4.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Harvard Bioscience is outperforming or lagging.

Tracking HBIO's total liabilities over time shows whether Harvard Bioscience is scaling, shrinking, or reshaping that part of the business. The current reading is $68M That compares with $65M in the prior-year period — up 4.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Harvard Bioscience's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $68M) with ownership activity and broader fundamentals.

Harvard Bioscience's total liabilities is $68M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.